Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults

被引:109
作者
Halperin, SA
Dobson, S
McNeil, S
Langley, JA
Smith, B
McCall-Sani, R
Levitt, D
Van Nest, G
Gennevois, D
Eiden, JJ
机构
[1] Dalhousie Univ, Clin Trials Res Ctr, IWK Hlth Ctr, Halifax, NS B3K 6R8, Canada
[2] British Columbia Childrens Hosp, Vaccine Evaluat Ctr, Vancouver, BC, Canada
[3] Dynavax Technol Corp, Berkeley, CA USA
关键词
hepatitis B vaccine; immunostimulatory sequences; randomized clinical trial;
D O I
10.1016/j.vaccine.2005.08.095
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background:: Many individuals do not respond to a three-dose series of hepatitis B vaccine (HBV) and most do not achieve a protective antibody response until after dose 2 or 3. Methods:: Healthy, seronegative 18-28 year old adults were randomly assigned in equal numbers to receive two doses of the experimental vaccine (HBV-ISS without alum) (0, 8 weeks) and placebo (24 weeks) or Engerix-B-(R) (0, 8, 24 weeks). Adverse events were collected during the first week and at 4 weeks after each injection. Antibodies were measured 4 weeks after dose 1; before, 1 and 4 weeks after dose 2, and before, 1 and 4 weeks after dose 3 and at 1 year. Results:: Ninety-nine participants were enrolled (65% female; mean age 22.6 years). 79% of HBV-ISS and 12% of Engerix-B-(R) recipients had a protective antibody response 4 weeks post dose 1 (geometric mean concentration [GMC] 23.0 and 1.87 mIU/mL, respectively). By 1 week post dose 2, 100% of HBV-ISS and 18% Engerix-B-(R) recipients had protective levels (GMC 1603 versus 2.40 mIU/mL). Rates of adverse events were low and similar in both groups; headache and fatigue were the most common systemic adverse events in up to 1/3 of both groups. Mild injection-site tenderness was more common after HBV-ISS than Engerix-B-(R) after both doses (74-77% compared to 34-58%; p <= 0.029). Conclusions:: Protective levels are achieved more quickly and after fewer doses of HBV-ISS than Engerix-B-(R). HBV-ISS is well tolerated but associated with more mild injection-site tenderness than Engerix-B-(R). (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:20 / 26
页数:7
相关论文
共 30 条
[1]   A hepatitis B vaccine formulated with a novel adjuvant system [J].
Ambrosch, F ;
Wiedermann, G ;
Kundi, M ;
Leroux-Roels, G ;
Desombere, I ;
Garcon, N ;
Thiriart, C ;
Slaoui, M ;
Thoelen, S .
VACCINE, 2000, 18 (20) :2095-2101
[2]  
ANDRE FE, 1987, POSTGRAD MED J, V63, P169
[3]   SUMMARY OF SAFETY AND EFFICACY DATA ON A YEAST-DERIVED HEPATITIS-B VACCINE [J].
ANDRE, FE .
AMERICAN JOURNAL OF MEDICINE, 1989, 87 (3A) :S14-S20
[4]  
[Anonymous], 1991, MMWR Recomm Rep, V40, P1
[5]  
BEASLEY RP, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P532
[6]   CPG-RICH ISLANDS AND THE FUNCTION OF DNA METHYLATION [J].
BIRD, AP .
NATURE, 1986, 321 (6067) :209-213
[7]   A randomized trial of alternative two- and three-dose hepatitis B vaccination regimens in adolescents: Antibody responses, safety, and immunologic memory [J].
Cassidy, WM ;
Watson, B ;
Ioli, VA ;
Williams, K ;
Bird, S ;
West, DJ .
PEDIATRICS, 2001, 107 (04) :626-631
[8]  
Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P618
[9]   HEPATITIS-B VACCINATION IN THE ELDERLY [J].
DENIS, F ;
MOUNIER, M ;
HESSEL, L ;
MICHEL, JP ;
GUALDE, N ;
DUBOIS, F ;
BARIN, F ;
GOUDEAU, A .
JOURNAL OF INFECTIOUS DISEASES, 1984, 149 (06) :1019-1019
[10]   A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant [J].
Halperin, SA ;
Van Nest, G ;
Smith, B ;
Abtahi, S ;
Whiley, H ;
Eiden, JJ .
VACCINE, 2003, 21 (19-20) :2461-2467